Garren Hideki's Form 4 filing
Prothena Corp Public Ltd Co (PRTA) · filed Jul 12, 2023
- Accession no.
- 0001140361-23-034304
- Filed
- Jul 12, 2023
- Trade date
- Jul 12, 2023
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $135.0K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Garren HidekiCIK 0001854126 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 12, 2023 | Ordinary Shares, par value $0.01 per share | MOption exerciseAcquired | +2,000 | $24.90 | +$49,800 | 2,000 | Direct | |
| Jul 12, 2023 | Ordinary Shares, par value $0.01 per share | SSaleDisposed | −1,908 | $67.48F2 | −$128,751.84 | 92 | Direct | |
| Jul 12, 2023 | Ordinary Shares, par value $0.01 per share | SSaleDisposed | −92 | $68.20F3 | −$6,274.4 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 12, 2023 | Ordinary Shares | MOption exerciseDisposed | −2,000 | $0.00 | $0 | 196,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The transaction was executed in multiple trades in prices ranging from $66.94 to $67.86, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 3 of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The transaction was executed in multiple trades in prices ranging from $68.12 to $68.20, inclusive.
Referenced by the price of 1 transaction in Table I.